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Disulfide links of the IgGZak anti-ovarian carcinoma anti- 
body, 5G6.4, were site-specifically biotinylated [z 2 biotins/ 
IgG2a] using a novel crosslinking procedure using the biotin 
derivatized ETAC (equilibrium transfer alkylation crosslink 
reagent) la. Complexation of ETAC la biotinylated 5G6.4 
on a column of immobilized protein A at high dilution, 
followed by passage of [i251]streptavidin, washing and pH 
change leads to elution of a streptavidin-free product with 
a molecular mass in the 200-300 kDa range. By contrast, 
direct mixing with [i2Qstreptavidin rapidly gave larger 
oligomers of $669 and x440-669 kDa molecular mass, 
respectively. The biodistribution of the 200-300 kDa com- 
plex showed significantly diminished liver, kidney and 
spleen uptake as well as higher blood activity than the 
W-669 kDa complex. The methodology represent the first 
application of ETAC chemistry to disulfide-bond directed 
biotinylation of antibodies and the synthesis of streptavidin 
antibody conjugates which minimizes their polymerization. 
Developments in the use of biotinylated antibodies and 
pre-formed streptavidin biotinylated antibody complexes 
may have applicability to using such approaches in radio- 
immunoconjugate delivery (Hnatowich er al., 1987; 
Paganelli et al., 199Od; Pimm et al., 1988; Sinitsyn et al., 
1989). Successful clinical studies have been reported by at 
least two groups (Rowlinson et al., 1988; Paganelli et al., 
1990a,b,c). Recently, we reported our findings concerning 
the potential applications of sulfhydryl site-directed bio- 
tinylation as a means of better preserving the immuno- 
reactivity of biotinylated antibodies and thei; corresponding 
radiolabeled coniugates (de1 Rosario and Wahl. 1989. 1990). 
These earlier data-grew‘ from our initial observation that 
reduced interchain disulfide links of antibodies were readily 
mono-alkylated with an iodoacetamide derivative of biotin 
(de1 Rosario and Wahl, 1989). Following complexation with 
radio-streptavidin, the oligomeric conjugates retained in vivo 
immunological activity. However, we and others have recog- 
nized that proper control of molecular size and purification 
remains a key problem in the synthesis cf homogeneous 
streptavidin-biotinylated-monoclonal IgG complexes for 
use in radioimmunoimaging (Hnatowich et al., 1987). Here 
we describe a simple method for minimizing the molecular 
size of the conjugate formed upon reaction with streptavidin 
which allows excess streptavidin to be easily separated from 
product without HPLC purification. 
Biotinylation was accomplished using a novel procedure 
using the “ETAC” (equilibrium transfer alkylation) cross- 
link reagent la, prepared in our laboratories (de1 Rosario 
et al., 1989, 1990) (Fig. 1). In previous work (de1 Rosario 
et al., 1989, 1990; Liberatore et al., 1990) we have shown 
that ETAC reagents provide a unique site-specific pathway 
for attaching a wide range of bioprobes to antibodies, i.e. 
through insertion and formation of a stable three carbon 
crosslinked disulfide bridge (de1 Rosario et al., 1990). In 
contrast to our earlier papers, ETAC biotinylation proceeds 
through a bis-alkylation as opposed to a mono-alkylation 
(as in the reaction of haloacetyl derivatives) of disulfide 
bonds (de1 Rosario and Wahl, 1989, 1990). 
We have recently reported the synthesis of the parent 
compound carboxy ETAC 1 and a biotin derivative, la 
(de1 Rosario et al., 1989). Biotinylated ETAC la (Fig. 1) 
was prepared by carbodiimide-mediated derivatization of 
carboxy-ETAC 1 with commercially available 5-(((N- 
biotinoyl)aminohexanoyl)amino)pentylamine (Molecular 
Probes) (de1 Rosario et al., 1989). The anti-ovarian carci- 
noma IgGZak antibody, 566.4 (Wahl et al., 1986) was 
chosen for the present study. 566.4 (produced from mouse 
ascites and purified by protein A chromatography) in 0.1 M 
sodium phosphate (pH z 7) solution was reduced (37”C, 
5 h) with a z 150 molar excess of DTT (Aldrich Chemical 
Co.). The mixture was treated with a DMSO solution of 
ETAC la (1: 1 molar ratio with resnect to DlT). vortexed 
and the emulsion allowed to react for 15-24 h at’j7”C. The 
reaction mixture was vortexed (15 min) and the clear super- 
natant desalted over Sephadex G-25 using 0.1 M sodium 
phosphate buffer @H ~7). 
Site-specific crosslinking and biotinylation of interchain 
disultide links of 5G6.4 was confirmed by reducing 
SDS-PAGE analysis (Pharmacia Phast System) of the 
crosslinked products. Since the new -S-{biotinoyl- 
ETAC}-S- chemical bonds were stable even at 100°C and 
not cleaved by reducing thiols, the crosslinked species 
appeared as new bands of xH,L,, H,L, H, and HL mass 
units in addition to uncrosslinked heavy (H) and light (L) 
chains on electrophoresis. These observations were identical 
to our previous findings (de1 Rosario et al., 1989, 1990; 
Laemmli, 1970; Liberatore et al., 1990). Laser densitometric 
measurement (Pharmacia Ultrascanner) of the Coomassie 
blue content on each band allowed calculation of an average 
of ~2 interchain H-H and H-L disulfide attached biotins 
per biotinylated 566.4 molecule (de1 Rosario et al., 1989, 
1990). As expected the extended “spacer arm” of the new 
biotin derivative la allowed facile complexation with strep- 
tavidin as has been observed with derivatives of N-hydroxy- 
succinimide esters of biotin (Hnatowich et al., 1987). 
Reaction of biotinylated 5G6.4 (MW x 150,000) with 
[‘251]streptavidin (MW r 60,000) in approximately equi- 
molar ratios led to formation of complex oligomeric mix- 
tures covering the z 400,000 to B 669,000 molecular mass 
region. The molecular weights of these conjugates were 
estimated from calibration plots of known standards using 
Pharmacia Superose 6 and 12 size-exclusion radio-FPLC 
as previously described (de1 Rosario and Wahl, 1990). 
Figure 2(a) shows a representative product profile. With 
excess biotinylated 566.4, the predominant species was 
mass 9669 kDa (species A), whereas ~2 or more molar 
equivalents of streptavidin per mole of biotinylated 566.4 
favored species in the lower 400-669 kDa mass range 
(Species B). *Author for correspondence. 
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Fig. 1. Chemical structures of ETAC 1 and biotin derivative la. 
Retention of immunoreactivity of the biotinylated and 
streptavidin-biotinylated 566.4 pre-formed complexes was 
verified by direct cell binding assays of the radiolabeled 
complex using human 77 IP3 target cells (de1 Rosario and 
Wahl, 1990). Direct binding of biotinylated 506.4 was 
indicated by specific binding (60%) of [‘251]streptavidin on 
target cells pre-incubated with the biotinylated 566.4 conju- 
gate. Preformed oligomeric species A ( %- 669 kDa) or- B 
(x400-> 669 kDa) IFig. 2(a)l both exhibited comnarable 
or better (60-8O%j specilfic binding than [‘ZsI]5G6.4 
@O-65%) labeled via the iodogen method (at substantial 
antigen excess). Flow cytometry results using fluorescent 
streptavidin were identical with those previously reported 
for the iodoacetyl-biotin conjugate of 566.4 (de1 Rosario 
and Wahl, 1989, 1990). Species A [Fig. 2(b)] showed excel- 
lent stability in serum (5 days) as assessed by radio-FPLC. 
Similarly, complex formation was observed when ETAC 
la biotinylated 566.4 was allowed to mix with radio- 
labeled streptavidin in serum (Z 1 fig biotinylated 
5G6.4/mL serum) instead of buffer. The preservation of 
immunoreactivity and stability data are consistent with the 
hypothesis that ETAC conjugation occur at sites distant 
from the antigen binding sites and leads to relatively stable 
biotin ETAC la crosslinks in 566.4. However, a prelimi- 
nary biodistribution study (mice, n = 3/group) of product 
complex enriched in species A (B669 kDa) showed large 
liver (0.263* f 0.016) and spleen (0.539 + 0.134) uptake 
with very little blood (0.006 + 0.001) pool activity by 48 h 
in comparison to a 150 kDa radiolabeled non-specific 
IgG2a antibody (UPC-IO) [liver: 0.055 f 0.006; spleen: 
0.167 k 0.026; blood: 0.111 + 0.066, P $0.0005, P C 0.025, 
P 6 0.10, respectively.*] The above results closely parallel 
our previous studies concerning the effect of added anti- 
mouse antibody on the in vivo behavior of circulating intact 
radiolabeled UPC-10 and 5G6.4 (Wahl and Fisher, 1987) 
and implied that large complex size would present a sub- 
stantial problem in targeting these antibody conjugates to 
tumors. 
*All values are in % kg ID/g (f SEM). 
To minimize formation of very large inter-antibody strep- 
tavidin oligomers (and their undesired non-target uptake in 
the liver and spleen), an alternative approach was devised 
using a protein affinity matrix. The strategy begins by first 
“anchoring” the same lot of biotinylated 566.4 on protein 
A (via its Fc portion) at pH 8-9 (Ey et al., 1978). [‘2sI]Radio- 
streptavidin was passed through the column briefly at high 
dilution to allow contact with the protein A-bound IgG. 
Unbound [‘251]streptavidin was then washed away and the 
5G6.Cbiotinylated streptavidin conjugate was saturated by 
passing a saturated buffer solution of biotin through the 
column to block available biotin binding sites on the 
streptavidin while still being bound to protein A. The 
product complex was conveniently eluted from off the 
column by washing at pH 5. 
A representative procedure is as follows. The above 
ETAC la-biotinylated 5G6.4 was thoroughly mixed with 
immobilized Protein A (Repligenm, ~200-300 pg IgGZa/ 
5 mL gel) suspended in 0.1 M sodium phosphate buffer 
(pH zz 8-9). The slurry was poured into a column. 
[‘251]Streptavidin (30-40 @i/pg, 100-300 PCi) was allowed 
to run through the column once. The column was washed 
several times with a saturated solution of biotin in 0.1 M 
@H x 8-9) sodium phosphate buffer until the eluent 
showed no change in background activity. Product complex 
was then eluted with 0.1 M citrate buffer at pH 5 (x 80 pCi) 
and examined for free streptavidin by size-exclusion radio- 
FPLC [Pharmacia Superose 6, Fig. 2(c)] analysis. 
Products of significantly lower molecular weight 
(~200,000-300,000) with radio-FPLC profiles such as C 
[Fig. 2(c)] were eluted at pH 5. The shoulder of peak C 
(higher molecular mass) in Fig. 2(c) was evident even when 
the radio-streptavidin used was partially blocked with <4 
equivalents of biotin prior to contact with the immobilized 
biotinvlated IaG. The biodistribution of suecies C was then 
compared with species B in rats (n = 3) and is summarized 
in Fig. 3. The biodistribution (rats, n = 3/group, t = 48 h) of 
species C showed significantly diminished liver, kidney and 
spleen uptake as well as higher blood activity than the 
440-669 kDa complex {liver ~2.4 [ratio of 440-669 kDa/ 
200-300 kDa activity], P C 0.025; kidney s 2.7, P < 0.005; 
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Fig. 3. Biodistribution of biotinylated X6.4 streptavidin complexes in rats (n = 3) as a function of size 
(species B: hatched; species C: solid). 
spleen 
In conclusion the above results provide (a) the first 
x3.8, P 6 0.01; blood [440-669 kDa 200- 
example of site-specific biotinylation via a unique mechan- 
300 kDa] x 0.35, P Q 0.005). Liver and spleen to blood 
ratios were decreased by z8 x (P d 0.05) and = 13 x 
ism of concomitant crosslinking of reduced disulfide links, 
(P Q 0.05) for the 200 kDa complex relative to the 
440669 kDa product. The improved retention of the lower 
(b) further illustrates the relevance of immunoconjugate size 
molecular weight complex in the blood appears due to 
avoiding high level delivery to the liver and spleen. Further- 
more, this should result in better contact between the 
in tissue localization, (c) demonstrates that improvements 
antibody and antigens present on tumor targets thus 
in biodistribution can clearly be achieved with a smaller 
improving immunoconjugate targeting (Hnatowich et al., 
1987). 
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